Scarica l'app Stockscreener
7.94
0.00%
0.00
Pre-mercato:
7.92
-0.02
-0.25%
Precedente Chiudi:
$7.94
Aprire:
$7.98
Volume 24 ore:
6,781
Relative Volume:
0.54
Capitalizzazione di mercato:
$22.35M
Reddito:
$22.03M
Utile/perdita netta:
$-19.91M
Rapporto P/E:
-0.4289
EPS:
-18.5137
Flusso di cassa netto:
$-16.84M
1 W Prestazione:
+12.62%
1M Prestazione:
+9.52%
6M Prestazione:
+13.73%
1 anno Prestazione:
-47.90%
Intervallo 1D:
$7.4789
$7.98
Intervallo di 1 settimana:
$6.3972
$7.9996
Portata 52W:
$4.14
$15.18
Lifeward Ltd Stock (LFWD) Company Profile
Nome
Lifeward Ltd
Settore
Industria
Telefono
15082511154
Indirizzo
2 CABOT ROAD, HUDSON
Compare LFWD vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LFWD
Lifeward Ltd
|
7.94 | 22.35M | 22.03M | -19.91M | -16.84M | -18.51 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Lifeward Ltd Stock (LFWD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-10 | Iniziato | Laidlaw | Buy |
| 2017-04-03 | Downgrade | Barclays | Equal Weight → Underweight |
| 2016-12-16 | Iniziato | Oppenheimer | Outperform |
| 2016-07-15 | Iniziato | Piper Jaffray | Overweight |
| 2015-05-22 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2015-05-08 | Reiterato | Barclays | Equal Weight |
| 2014-10-07 | Iniziato | Barclays | Equal Weight |
Mostra tutto
Lifeward Ltd Borsa (LFWD) Ultime notizie
H.C. Wainwright Maintains Lifeward(LFWD.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Lifeward (LFWD) Q4 2025 Earnings Transcript - AOL.com
LFWD Technical Analysis | Trend, Signals & Chart Patterns | LIFEWARD LTD (NASDAQ:LFWD) - ChartMill
Lifeward’s Earnings Call Balances Setbacks and Strategy - The Globe and Mail
Lifeward (Nasdaq: LFWD) posts wider Q1 loss, adds Oratech and new convertible debt - Stock Titan
Lifeward (LFWD) Chief Medical Officer receives 15,000-share RSU award - Stock Titan
Lifeward (LFWD) Chief Medical Officer discloses 2,083 ordinary shares - Stock Titan
Lifeward Ltd. Appoints Keith D. Rose, M.D. as Chief Medical Officer – SEC 8-K Filing May 2026 - Minichart
Lifeward promotes Keith Rose to chief medical officer By Investing.com - Investing.com Nigeria
Lifeward appoints Keith D. Rose, M.D. as chief medical officer By Investing.com - Investing.com Australia
Lifeward appoints Keith D. Rose, M.D. as chief medical officer - Investing.com
Lifeward Names Keith D. Rose as Chief Medical Officer - TipRanks
Lifeward (NASDAQ: LFWD) appoints Keith D. Rose, M.D. as new CMO - Stock Titan
Lifeward promotes Keith Rose to chief medical officer - Investing.com
Lifeward Appoints Dr. Keith D. Rose as Chief Medical - GlobeNewswire
Lifeward Ltd.16079622026 - SEC.gov
Lifeward (LFWD) price target decreased by 37.93% to 4.59 - MSN
How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions - Yahoo Finance
Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth Opportunities - GuruFocus
Number of shareholders of Lifeward Ltd. – BOATS:LFWD - TradingView
Lifeward Earnings Call Balances Growth With Disruptions - TipRanks
Lifeward Q1 earnings preview - MSN
Earnings Call Summary | Lifeward(LFWD.US) Q1 2026 Earnings Conference - 富途牛牛
Lifeward 1Q Loss/Shr $6.70 >LFWD - Moomoo
Lifeward Q1 2026 Loss Deepens: -$3.13/Share vs -$0.34 Expected - AlphaStreet
Lifeward Ltd (LFWD) Q1 2026 Earnings Miss: EPS -$6.70 vs -$1.26 - GuruFocus
Lifeward (LFWD) Q1 2026 Earnings Transcript - AOL.com
Lifeward expects 2026 revenue similar to 2025 following Oratech acquisition and $10M convertible note financing - MSN
Lifeward Ltd. Q1 2026 Earnings Call Summary - Yahoo Finance
Lifeward (LFWD) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Lifeward Ltd. Closes Oratech Acquisition, Receives $10M Financing, Launches Phase 2 Oral Insulin Trial, and Expands Exoskeleton Technology for Stroke Rehabilitation - Minichart
Transcript : Lifeward Ltd., Q1 2026 Earnings Call, May 15, 2026 - marketscreener.com
Lifeward Ltd (NASDAQ:LFWD) Q1 Revenue Misses Estimates as Strategic Transformation Takes Shape - ChartMill
Lifeward Delays Quarterly Report Amid Deal Accounting - TipRanks
Lifeward Releases Q1 2026 Financial Results - AlphaStreet
LFWD: Q1 revenue fell on AlterG delays, but ReWalk sales and liquidity improved with new acquisitions - TradingView
Earnings call transcript: Lifeward’s strategic moves amid Q1 2026 challenges - Investing.com
LFWD: Revenue fell on AlterG delays, but ReWalk sales and liquidity improved; outlook remains stable - TradingView
Lifeward Q1 2026 Earnings Call Transcript - Benzinga
Lifeward: Q1 Earnings Snapshot - WKYC
[NT 10-Q] Lifeward Ltd. SEC Filing - Stock Titan
Lifeward 1Q Rev $3.92M >LFWD - Moomoo
Press Release: Lifeward Reports First Quarter 2026 Financial Results - Moomoo
Lifeward (Nasdaq: LFWD) posts Q1 2026 loss and boosts cash via deals - Stock Titan
Lifeward Reports First Quarter 2026 Financial Results - GlobeNewswire
Oramed Pharmaceuticals Discloses Investment at Lifeward with 49.9% Stake - TradingView
Oramed details Lifeward (LFWD) equity stake, notes and warrants - Stock Titan
Oramed (LFWD) reports 49.9% Lifeward stake, $9M notes and warrants - Stock Titan
Walk Assist Robot Market Research Report 2026-2031: Leading firms Such as Ekso Bionics, Lifeward, Cyberdyne, Ottobock, and DIH Medical Lead the $568.81 Million Market - Yahoo Finance
Lifeward Ltd expected to post a loss of $1.25 a shareEarnings Preview - TradingView
TradingKey - TradingKey
Lifeward Ltd Azioni (LFWD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
1.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):